How Rwanda mounted a research response with an investigational vaccine just ten days into a Marburg outbreak.

IF 6.5 1区医学 Q1 IMMUNOLOGY

NPJ Vaccines Pub Date : 2025-08-01 DOI:10.1038/s41541-025-01224-8

Sabin Nsanzimana, Noella Bigirimana, Richard Hatchett, Sue Bailey, Natacha Butera, Yvan Butera, Jakob P Cramer, Amy Finan, Caroline M Forkin, Adam M Hacker, Sibomana Hassan, Vicky Leamy, Vincent Mutabazi, Julien Nyombayire, Eric Remera, Edson Rwagasore, Eduardo Tedeschi, Kelly L Warfield, Nicole Lurie

引用次数: 0

Abstract

The September 2024 outbreak of Marburg virus disease (MVD) represented the first time this virus was identified in Rwanda. Health authorities mounted a rapid and effective response, including the rapid execution of an open-label Phase 2 clinical trial of an investigational Marburg vaccine, beginning just 10 days after the outbreak was declared. We share lessons from this rapidly executed clinical trial to help encourage outbreak research preparedness in other countries.

Abstract Image

查看原文本刊更多论文

卢旺达是如何在马尔堡疫情爆发10天后，用一种研究性疫苗开展研究应对的。

2024年9月暴发的马尔堡病毒病是卢旺达首次发现这种病毒。卫生当局采取了迅速而有效的应对措施，包括在宣布疫情暴发后仅10天就迅速开展了一种研究性马尔堡疫苗的开放标签第二期临床试验。我们分享这一快速实施的临床试验的经验教训，以帮助鼓励其他国家做好疫情研究准备。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Vaccines Immunology and Microbiology-Immunology

CiteScore

11.90

自引率

4.30%

发文量

146

审稿时长

11 weeks

期刊介绍： Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.